Bracco Diagnostics

TriMed Staff | | Health Imaging | Screening
 
Bracco’s MultiHance MRI contrast agent 
Bracco Diagnostics (Booth 2845), along with ACIST Medical Systems, is showcasing a portfolio of  imaging agents and delivery systems, such as MultiHance, which is indicated for intravenous use in MRI of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues.

MultiHance (gadobenate dimeglumine) is an MRI contrast agent that has nearly twice the relaxtivity of other gadolinium-based contrast agents providing a marked increase in signal-to-noise ratio in T1-weighted images, the company says. The agent demonstrates transient weak and interactions with serum proteins that causes slowing in the molecular tumbling dynamics.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.